Stock vs Stock Comparison

Pfizer Inc. vs Abbott Laboratories

ABT wins the Tale of the Tape 5–3.

PFE$25.55
ABT$86.97

🏆 Tale of the Tape

35
PFEABT
12.4%Profitability (Net Margin)14.7%
20.0xValuation (P/E)24.0x
4.7%Efficiency (ROIC)10.1%
5/9Health (Piotroski F)5/9
2.0Safety (Altman Z)4.9
-1.7%Growth (Rev YoY)5.7%
0.97Risk (Sharpe 1Y)-1.05
1.40xBalance Sheet (D/E)0.64x
4.26%FCF Yield4.21%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.228
252-Day Correlation
0.276
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricPFEABT
Market Cap$149.2B$149.1B
P/E Ratio20.0x24.0x
Forward P/E9.2x14.1x
P/B1.66x2.86x
Dividend Yield6.57%2.94%
Beta0.300.65

Quantitative Metrics

MetricPFEABT
DCF Fair Value$21.77$57.20
DCF Upside-20.4%-43.2%
Piotroski F5/95/9
Altman Z2.024.87
Beneish M-2.48-2.53
FCF Yield4.26%4.21%
Net Debt/EBITDA3.6x0.1x
ROIC4.7%10.1%
WACC6.9%9.4%
ROIC – WACC-2.1pp0.7pp
Gross Margin74.3%56.4%
Net Margin12.4%14.7%
Rev Growth YoY-1.7%5.7%
Sharpe (1Y)0.97-1.05
Max Drawdown 3Y
FCF Payout Ratio108%56%

PFE Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

PFE found in:

SPHD2.93%
XLV2.75%
VHT2.46%
DVY1.89%
XPH1.73%
SPYD1.19%
MGV0.75%
VFVA0.74%
VYM0.63%
VTV0.59%
SCHV0.53%
IWD0.52%
SPYV0.51%
VONV0.46%
ESGV0.32%
QUS0.27%
SCHX0.25%
VOO0.25%
IVV0.24%
SCHB0.24%
SPLG0.23%
SPY0.23%
VONE0.23%
VTI0.22%
ITOT0.21%
SPTM0.21%
RSP0.20%
URTH0.18%
ACWI0.16%
VT0.13%
ONEO0.10%

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

PFE vs ABT: Head-to-Head Analysis

Pfizer Inc. (PFE) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABT leads 5–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, PFE generates a return on invested capital (ROIC) of 4.7% compared to ABT's 10.1%. This suggests ABT is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between PFE and ABT is 0.228, indicating low correlation, making them an effective diversification pair in a portfolio context.

PFE appears in 31 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, PFE or ABT?

Our quantitative analysis compares PFE and ABT across nine fundamental dimensions. ABT wins the Tale of the Tape 5–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are PFE and ABT correlated?

The 252-day correlation between PFE and ABT is 0.228. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.